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Background:The goal of this study was to review the currently available literature and to compare the short and long-term
results of primary stenting and angioplasty of femoropopliteal occlusive disease by performing a meta-analysis review.
Methods: A systematic review of the literature that was published between September 2000 and January 2007 was
performed. All studies that reported data on the long-term results after balloon dilatation or stent implantation were
included if at least one-year primary patency or restenosis rate was presented; the study follow-up was at least 1 year and
the number of subjects at the start of study was at least 20 patients. Three investigators independently extracted the data.
The Pooled survival curves were then constructed for graft patency according to a random-effects protocol for
meta-analysis.
Results:Twenty-four articles were initially identified but only seven were selected and included in this meta-analysis: seven
were RCTs publications and one was a retrospective study comparing the outcome of angioplasty and stenting of the
femoropopliteal segment. In our meta-analysis, there were a total of 934 patients with 452 patients who underwent
balloon angioplasty (273 patients were male) and 482 patients who underwent stenting (297 patients were male).
Primary patency at 1-year and postoperative ABI post intervention was used to evaluate the pooled odds ratio (OR) of all
studies. The pooled OR of all studies estimate for the 12-month patency rates was 0.989 (95% confidence interval [CI],
0.623 to 1.570, P .962) showing no difference in outcome between the two groups (SE 0.269% to 1.025%). The pooled
OR estimate for the postoperative ABI was 0.869 (95% CI, 0.557 to 1.357, P .561) showing a slight advantage in favor
of the angioplasty group but the P value was not statistically significant (SE 0.282% to 1.326%). The 1-year primary
patency rates following balloon angioplasty ranged from 45% to 84.2% and at 2 years it varied from 25% to 77.2%. In the
stent implantation group, the 1-year primary patency rates varied from 63% to 90%, and 2-year primary patency ranged
from 46% to 87%. Heterogeneity was seen among studies, and publication bias could not be excluded.
Conclusions: The results of our meta-analysis suggest that stent placement in the femoropopliteal occlusive disease does
not increase the patency rate when compared with angioplasty alone at 1 year. This conclusion should be viewed in the
light of study-design considerations and all limitations in this meta-analysis that may have an impact of the outcome of
stenting and angioplasty after a 1-year follow-up. (J Vasc Surg 2008;47:461-9.)Considerable advances have been made over the last
decade in percutaneous technology for the treatment of
atherosclerotic diseases in the iliac, femoropopliteal, and
distal tibioperoneal arteries.1,2 The techniques that have
been developed include percutaneous balloon angioplasty
and stenting, atherectomy and laser therapy.1,3,4
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doi:10.1016/j.jvs.2007.07.059Is stenting better than angioplasty in the SFA for man-
aging patients with femoropopliteal arterial disease? Two
meta-analyses have addressed this issue. The first by
Hunink et al5 describe the patency results of percutaneous
transluminal angioplasty and bypass surgery in the treat-
ment of femoropopliteal arterial disease. Stenting results of
the femoropopliteal segment were not included. The sec-
ond meta-analysis was by Muradin et al6 where they review
the currently available data on the long-term results follow-
ing balloon dilation and assess the influence of stent place-
ment in the treatment of femoropopliteal arterial disease.
The aim of this study was to review the currently available
literature andperformameta-analysis on the results of primary
stenting of femoropopliteal occlusive disease and angioplasty
of the femoropopliteal occlusive disease.
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Design
We used the reporting standards for lower extremity
ischemia criteria, the TransAtlantic Inter-Society Consen-
sus (TASC) classification7 and the Cochrane Database of
Systematic Reviews (CDSR). Key reporting standard crite-
ria include: clinical categories of chronic limb ischemia,
standard risk factors such as diabetes, hypertension, hyper-
cholesterolemia, and smoking should be reported along
with the outcomes of revascularization for lower extremity
ischemia. The criterion for defining the various outcomes
in the studies selected should be clearly established (pa-
tency, limb salvage, clinical status, or quality of life). Reste-
nosis was defined as a greater than 50% diameter reduction
in the segment. Primary patency means “freedom from
developing more than 50% restenosis that does not require
any surgical procedure, or an endovascular procedure per-
formed to deal with disease progression. If vessel patency
was restored with endovascular procedures after occlusion,
it was listed as secondary patency. Primary failures refer to
both technical and early hemodynamic failures. The need
for an additional procedure (stent placement) during pri-
mary PTA was considered a primary failure. Technical
failure refers to the inability to pass through the lesion or to
residual stenosis greater than 30% at angiography immedi-
ately after PTA. To reduce bias, prospective studies that had
20 ormore participants, with good descriptions of methods
of patient recruitment and selection were sought. Studies
published with an abstract only provided insufficient data
and were excluded.
Data sources (search strategy)
A comprehensive search of PUBMED and MEDLINE
database of literature Embase from 1980 to January 2007,
the science citation index from 1990 until 2007, and the
Cochrane controlled trials registry was completed. There
Table I. A review of the study population characteristics a
balloon dilation
Studies N Age† Sex 1
Krankenburg* 2006 121 66 91/30 N/A
Schillinger 200616 53 68 25/28 0
Grenacher 200417 53 66.1 37/16 0
Becquemin 200318 112 66 66/46 89
Saxon 200319 13 72.6 N/A N/A
Pozzi Mucelli 200320 63 67 42/21 30
Cejna 200121 77 65.5 46/31 N/A
Grimm 200122 23 68.1 10/13 N/A
N, Number of legs; Sex, (male/female ratio); SVS/ISCVS, Society of Vas
available; SFA(P), proximal superficial femoral artery; SFA(M), mid-superfi
ABI, ankle-brachial index (preoperative/postoperative); 0-yr, 6 months; yr
All data are absolute number except patency rate, which are percentage.
*FAST trial is still not published yet.
†Mean or median age, depending on what authors reported.was no language or other restrictions. The search consistedof the following terms: randomized, control, trial or clinical
trial, evidence-based medicine, controlled study, femoro-
popliteal artery occlusive disease, stenosis, angioplasty, bal-
loon dilatation, limb salvage, claudication, femoral, popli-
teal, patency, failure rate, stent fracture, stents, life table,
restenosis, arterial occlusive disease, arteriosclerosis, follow-up
studies, and stenting. In addition, the reference lists of
identified articles were checked to obtain additional rele-
vant articles. Reference lists of papers resulting from this
search were also hands searched, and authors of published
trials were contacted to enquire if necessary.
A systematic review of the literature that was published
between September 2000 and January 2007 was performed.
The review was restricted to this period for two reasons: First,
two previous meta-analyses that include balloon angioplasty
and stenting were published between January 1985 and Jan-
uary 1993; and between January 1993 and August 2000.5,6
Second, technology of angioplasty balloon and stenting has
advanced rapidly since the turn of the century.
A librarian crosschecked the accuracy of the data re-
trieval. In addition to the abstract search in the MEDLINE
database, references were obtained from the bibliographies
of retrieved articles and the Internet. If the abstract of an
article provided sufficient information to conclude that the
authors did not report results after endovascular interven-
tion, the full article was not retrieved. These articles were
excluded on the basis of the abstract alone. All other articles
were retrieved, reviewed, and analyzed. Unpublished data
was included if they met the requirement as stated above
and the full data could be retrieved from the authors.
Articles published in German (translated into English by
MH) and French (translated into English by BPM) were
included in the final analysis.
Study selection
Criteria for considering studies for this review. All
atency results for studies that included femoropopliteal
SVS
Stenosis Occlusion2 3 4 5/6
N/A N/A N/A N/A N/A N/A
0 46 2 5 36 17
8 32 4 9 33 20
N/A N/A 7 16 91 21
N/A N/A N/A N/A 13 0
33 N/A N/A N/A 40 23
13 45 7 12 52 25
N/A N/A N/A N/A 20 3
Surgery/International Society of Cardiovascular Surgery (14); N/A, not
moral artery; SFA(D), distal superficial femoral artery; PA, popliteal artery;
s.nd p
cular
cial fe
s, yearstudies that reported data on the long-term results after
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(a) at least 1-year primary patency or restenosis rate was
presented; (b) the study follow-up was at least 1 year;
(c) the number of subjects at the start of study was at least
20 patients and (d) the number of initial failures and type of
stent were reported. We included only studies with patients
aged more than 18 years who had femoropopliteal le-
sions.7,8 Studies analyzing patients with nonocclusive ath-
erosclerotic disease of femoropopliteal segment, studies
with less than 20 patients and nonatherosclerotic disease of
femoropopliteal segment were excluded.
Study quality. The Jadad score was used as the “gold
standard” to assess the methodological quality of random-
ized controlled trials (RCTs).9-12 This validated score lies
in the range 0 to 5. Studies were scored according to the
presence of three key methodological features of random-
ization, blinding, and accountability of all patients, includ-
ing withdrawals. For example, the score is two if appropri-
ate methods of randomization are described, one if the
study is merely described as “randomized” and zero when
no details are provided to evaluate randomization. Two
points can be given for blinding in the study: a score of two
is allocated if patients and investigators are made blind by
appropriate methods, one if the study is describedmerely as
double blind, and zero if details about blinding are not
provided. The third item to be scored is the reporting of
withdrawals. The study receives a score of one if all patients
are accounted for in the analysis and reasons for withdraw-
als are provided. A score of zero is given when information
regarding withdrawals is incomplete. A priori, it was de-
cided that studies should be scored as high quality if they
received a Jadad score of four or five (out of possible five
points) and low quality if the score was equal to or less than
three.
Data extraction
Three readers (BPM, MH, and MG) abstracted the
Table I. Continued
Poor runoff
SFA
PAP M D P
N/A N/A N/A N/A N/A 0.6
12 10 39 34 7 0.5
20 4 0 43 6 0.6
N/A 10 42 40 106 0.4
N/A N/A N/A N/A N/A 0.3
N/A N/A N/A N/A N/A 0.6
15 11 N/A 58 8 0.6
N/A N/A N/A N/A N/A 0.6data from each article independently by using a standard-ized form. The following data was recorded: outcomes
measures included changes in ABI (ankle-brachial index),
improvement of claudication distance, healing of wound,
stent fracture, patency of femoropopliteal segment, degree
of restenosis (the percent reduction of diameter of more
than 50% of the vessel diameter), major cardiovascular
complications (defined as a dissection of aortoiliac seg-
ment, myocardial infarction or angina, heart failure, hypo-
tension, death), and procedural complications (including
development of renal failure, reaction to contrast, need for
dialysis, local groin complications).
Stent fracture was classified as grade 1 or minor fracture
if there is a fracture of a single strut, grade 2 or moderate
fracture if there is a fracture of more than one strut; and
grade 3 or severe fracture if there is a complete stent
separation.
All RCTs with patients assigned to either primary bal-
loon angioplasty or primary balloon angioplasty and stent-
ing as the principal intervention were included in the final
analysis. If standard errors (SE) was not reported in the
study, it was estimated by using the Greenwood formula.13
Discrepancies in the extracted data were resolved in discus-
sion and the articles were examined together.
Statistical analysis
Data synthesis. All patency rates reported at multiple
times were analyzed together by using weighted multiple
linear regression according to the analysis of variance
(ANOVA). ANOVA consists of calculations that provide
information about levels of variability within a regression
model and form a basis for tests of significance. The depen-
dent variable in the regression models was the reported
patency rate, and independent variables were the times of
the reported patency rates. In the regression models, ad-
justments were made for the correlation between the re-
ported patency rates within the same study, and the inverse-
squared SE were used as weights. To adjust for differences
BI Patency rate (%)
Post 0-yr 1-yr 2-yrs 3-yrs 4-yrs
0.73 N/A 61 N/A N/A N/A
78 55 63 N/A N/A N/A
0.92 N/A 76.1 66.1 N/A N/A
0.96 N/A 77 70 N/A 44
0.47 42 45 25 N/A N/A
0.91 70 66 58 N/A N/A
0.97 78 72 65 N/A N/A
0.85 N/A 84.2 77.2 69.9 N/AA
re
1
4
0
2
9
1
2
2in case mix between the study populations, the baseline
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in the model were included. With use of multivariate back-
ward regression, variables and interaction terms with a
P value larger than .05 were eliminated. The models were
fitted with SPSS 11 for Mac OS X and Comprehensive
Meta-analysis and Excel for Window were used as software
for all statistical analysis.
Heterogeneity. Heterogeneity between the primary
studies initially using the Cochran’s Q results from a mod-
ified 2 test was tested. The Q test was, however, seen as an
unreliable test of heterogeneity because there was only
small number of trials (seven trials) included in the final
analysis. The I2 index was used, as it does not rely on the
number of studies analyzed, the type of outcome data or
the choice of treatment effect. The I2 value lies between 0%
and 100% and is presented with a 95% confidence interval.
Increasing I2 values indicate increasing heterogeneity and
are considered statistically significant if 50% or greater. The
random-effects model (DerSimonian-Laird method) was
used for data analysis because the null hypothesis of no
differences between the studies was rejected.14
Funnel plot. The funnel plot was used to test any
publication bias.15 An estimation of the overall result was
also expressed by using a Forest plot.15 In contrast to the
overall test of heterogeneity, the test for funnel plot asym-
metry assesses a specific type of heterogeneity. However,
any analysis of heterogeneity depends on the number of
trials included in a meta-analysis, which is small in this
meta-analysis, and this limits the statistical power of the
test. Therefore, the Egger’s Test of the Intercept has been
used to quantify or augment the display of the funnel plot
since most of the studies had a small sample size.
Sensitivity analysis. To assess the robustness of the
results used in this meta-analysis and the impacts on the
outcome of the findings, a sensitivity analysis was per-
Table II. A review of the study population characteristics
stent implantation
Studies N Age† Sex 1 2
Krankenburg* 2006 123 66 77/46 N/A N/
Schillinger16 2006 51 65 30/21 0
Grenacher17 2004 71 68.2 43/28 N/A 1
Becquemin18 2003 115 66 76/39 91 N/
Saxon19 2003 15 68 0 N/A N/
Pozzi Mucelli20 2003 23 67 16/7 N/A N/
Cejna21 2001 77 68.6 49/28 N/A 1
Grimm22 2001 30 70.5 22/8 N/A N/
N, Number of legs, Sex, (male/female ratio); SVS/ISCVS, Society of Vas
available; SFA(P), proximal superficial femoral artery; SFA(M), mid-superfi
ABI, ankle-brachial index (preoperative/postoperative); 0-yr, 6 months; yr
All data are absolute number except patency rate, which are percentage.
*FAST trial is still not published yet.
†Mean or median age, depending on what authors reported.formed.15RESULTS
A total of 1054 citations published between September
2000 and January 2007 were identified and screened. Of
these, only 255 were retrieved following the electronic
database search: 163 articles were retrieved from PubMed,
12 fromCochrane, 57 fromOVID, and 23 fromEMBASE.
Only 24 articles met the initial inclusion criteria. After
multiple reading and crosschecking of the 24 articles, only
seven were found to be RCTs publications comparing the
outcome of angioplasty and stenting of the femoropopliteal
segment. They were selected and included in this meta-
analysis. Two articles were in German and one was in Italian
with English translation. Fifteen articles were excluded for
the following reasons: (1) they were clinical studies with
either angioplasty or stenting as the treatment modality
alone; (2) combined analysis of treatment of multiple arte-
rial segments or mixed data could not separately retrieve
the angioplasty outcome result from the stenting result;
and (3) study sample of fewer than 20 patients, missing data
on initial failures, insufficient data to extract SE, or 1-year
patency.
Review
Seven studies were included in the final analysis that
gave details of 452 patients (273 patients were male) with a
mean age of 66.1 years (65.5 to 68.1) in the angioplasty
group and 482 patients (297 patients were male) with a
mean age of 67.5 years (65 to 70.5) in the stent group. The
extracted data from the articles included in the meta-analysis
ordered by publication year are outlined in Tables I and II.
In the angioplasty group, poor run-off vessels were
found in 47 patients; 28% of patients had a disease in the
popliteal segment. Major amputations were three and mi-
nor amputations were six. Maximal vessel length treated in
this group was 30.2 cm with a mean of 4.3 cm. Hyperten-
sion and smoking were predominant (61%); hyperlipidemia
patency results of studies that included femoropopliteal
SVS
Stenosis Occlusion Poor runoff3 4 5/6
N/A N/A N/A N/A N/A N/A
45 1 5 32 19 7
39 6 11 52 19 32
N/A 7 17 86 29 N/A
N/A N/A N/A 12 3 N/A
N/A N/A N/A 12 11 7
39 11 16 42 25 21
N/A N/A N/A 17 13 N/A
Surgery/International Society of Cardiovascular Surgery (14); N/A, not
oral artery; SFA (D), distal superficial femoral artery; PA, popliteal artery;
s.and
A
0
5
A
A
A
1
A
cular
cial fem
s, yearwas present in 54% of patients and diabetes mellitus in 31%
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in 6.4%. Overall complications was observed in 6%.
In the stent group, poor run-off vessels were found in
67 patients; 27% patients had disease in the popliteal seg-
ment. Major amputation occurs in four patients and minor
amputation in two patients. Maximal vessel length treated
in this group was 32 cm with a mean of 4.6 cm. Hyperten-
sion was present in 69%, smoking in 62.6%, hyperlipidemia
in 59.5%. Less than 30-day mortality was 4% with a failure
rate in 2%. Overall complications were observed in 11%.
The percentage of cases with an occlusion seems similar
between the two groups (19% in the angioplasty group vs
22% in stenting group). There were a total of 12 cases of
stent fracture reported without any impact on the patency
of the stent implanted. Different varieties of stents were
used (Luminexx, Murray Hill, NJ, Dynalink, Indianapolis,
Ind, Palmaz, Miami Lakes, Fla, Hemobahn, Flagstaff, Ariz,
Memotherm, Karlsruhe, Germany, Wallstent, Plymouth,
Minn). In three studies, balloon expandable stents were
used (mostly the Palmaz stent) in three studies. The two
latest studies used self-expandable stents (Luminexx by
Bard and Dynalink by Guidant). Stent fractures were re-
ported only with self-expandable stents. Follow-up periods
and baseline characteristics of the study populations dif-
fered markedly across the eight studies. Follow-up varied
from 6 months to 4 years.
The publication standard according to the TASC clas-
sification was not used in any of the studies but the SVS/
ISCVS classification was used in authors 2, 3, and 4, and
missing in authors 1, 5, and 7. Long-term use of anticoag-
ulation was inconsistent among the different studies mak-
ing it difficult to deduct any significant conclusion of the
outcome of anticoagulation on the patency of the stent and
angioplasty vessels.
Funnel plot
The basic issue of publication bias is that not all com-
Table II. Continued.
SFA
PA Stent
Stent
FractureP M D
N/A N/A N/A N/A N/A N/A
13 38 36 6 100 2
8 N/A 55 8 N/A N/A
9 46 41 112 100 N/A
N/A N/A N/A N/A 15 N/A
N/A N/A N/A N/A 23 0
17 N/A 56 4 N/A N/A
N/A N/A N/A N/A N/A N/Apleted studies are published, and the selection process is notrandom (hence, the “bias”). Rather, studies that report
relatively large treatment effects are more likely to be sub-
mitted and/or accepted for publication than studies that
report more modest treatment effects. Since the treatment
effect estimated from a biased collection of studies would
tend to overestimate the true treatment effect, it is impor-
tant to assess the likely extent of the bias and its potential
impact on the conclusions.
Egger suggests that we assess this same bias by using
precision (the inverse of the SE) to predict the standardized
effect (effect size divided by the SE). In this case, the
intercept (B0) is 1.169, 95% confidence interval (2.433,
4.770), with t  0.794, degrees of freedom (df)  6. The
one-tailed P value (recommended) is .229, and the two-
tailed P value is .457.
Pooled results
Primary patency at 1-year and postoperative ABI post
intervention was used to evaluate the pooled odds ratio
(OR) of all studies. The pooled OR of all studies estimate
for the 12-month patency rates was 0.989 (95% confidence
interval [CI], 0.623 to 1.570, P  .962) showing no
difference in outcome between the two groups. (SE
0.269% to 1.025%) (Fig 1). The pooled OR estimate for
the postoperative ABI was 0.869 (95% CI, 0.557 to 1.357,
P  .561) showing a slight advantage in favor of the
angioplasty group but the P value was not statistically
significant (SE 0.282% to 1.326%) (Fig 2).
The 1-year primary patency rates following balloon
angioplasty ranged from 45% to 84.2% and at 2 years it
varied from 25% to 77.2%. Only one study published the
4-year primary patency and that was 44% (no 4). In the
stent implantation group, the 1-year primary patency rates
varied from 63% to 90%; and 2-year primary patency ranged
from 46% to 87%. Only one study published the 4-year
primary patency, which was the same as in the angioplasty
ABI Patency rate (%)
e Post 6/12 1-yr 2-yrs 3-yrs 4yrs
0.68 N/A 68 N/A N/A N/A
7 0.9 75 63 N/A N/A N/A
A N/A N/A 66.1 49.1 N/A N/A
4 0.96 N/A 65 53 N/A 44
1 0.65 93 90 87 N/A N/A
1 0.93 74 67 46 N/A N/A
3 0.99 87 78 65 N/A N/A
7 0.91 N/A 75 72.4 73.3 N/APr
0.5
0.5
N/
0.7
0.5
0.6
0.6
0.4group. There were 28 cases of crossover from angioplasty
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Heterogeneity
To identify variables that may help explain some of the
residual heterogeneity, covariables representing baseline
characteristics of the study populations; namely, age, gen-
der (data available in six of seven studies), arterial run-off
(data available in three of seven studies), use of long-term
anticoagulation (inconsistent among the different studies)
and popliteal vs femoral localization of the lesion (data
available in four of seven studies) were tested inmultivariate
model. But only two variables were used to assess hetero-
geneity in all the studies. Those variables were not associ-
ated with a statistically significant regression parameter.
The P value was .062 with a Q value of 13.415, inverse-
squared (I-squared) of 55.274 for the primary patency at 1
year. The P value was .519 with a Q value of 4.833,
I-squared of 0 for the postoperative ABI. Heterogeneity
could not be explained but the absence of other significant
datamay influence it. Only the variables “poor run-off vessels,
preoperatively ABI” had a statistically significant contribution
in explaining the reported variation in patency rates (P .05,
CI 48.19 to 86.44 and P  .05, CI 45.20 to 97.15, respec-
Fig 1. Comparison of primary patency measure between the two
groups. The P value was .062 with a Q value of 13.440, I-squared
of 47.917 (Tau-squared test: Tau squared was 0.153 with standard
error 0.179, variance 0.032) for the primary patency at 1 year.
Fig 2. Comparison of postoperative ABI measure between the
two groups. The P value was 0.519 with a Q value of 5.196,
I-squared of 0 (Tau-squared test: Tau squared was 0 with standard
error 0.237, variance 0.056) for the postoperative ABI.tively).Regression analysis
The adjusted regression line shows that there is no
relationship between the log OR (primary patency) and
sample size between all the studies (of different sample
size). This may indicate that there might be a presence of
bias, which may explain other possible cause for heteroge-
neity between studies (Fig 3).
Sensitivity analysis
Exclusion of all articles, except the two most recent
studies using self-expandable stents, from the final model
did not have a large effect on the difference in discrimina-
tory power between the angioplasty group and primary
stenting. But the 1-year patency was nonsignificantly better
in the stenting group (OR 1.238 [95% CI: 0.798, 1.920];
P  .341 for both fixed and random models).
In a second sensitivity analysis, we excluded studies
with poorer quality, results very different from the rest of
the studies and studies with wider confidence interval (only
five studies were incorporated in the analysis). The studies
excluded were by Saxon et al that had a wider range of CI
and a small sample size. Studies by Grimm et al had a low
relative weight, low Jadad score (score of one). The exclu-
sion of these studies did not influence the final analysis.
There was a slight advantage for the angioplasty group but
it was not statistically significant (fixed method: OR 0.934
[95% CI: 0.696, 1.253]; P  .647 and random method:
OR 0.923 [95% CI: 0.616, 1.381]; P  .696).
Finally, an additional sensitivity analysis was performed
and this excluded the study by Krukenberg et al (not yet
published with missing data, only four studies were incor-
porated in the analysis). The difference was not significant
in comparison with results obtained from the initial analysis
of all eight studies together (fixed method: OR 0.787 [95%
CI: 0.552, 1.122; P.186 and randommethod: OR 0.803
[95% CI: 0.521, 1.237]; P  0.320).
DISCUSSION
A common cause of lower extremity claudication is
Fig 3. Regression analysis. Regression lines adjusted for the sam-
ple size from all eight studies. It shows that there is no relationship
between the log odds ratio (primary patency) and sample size
between all the studies (of different sample size), which may
indicate presence of publication bias.atherosclerotic occlusion of the superficial femoral artery.
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entzig in February 1974, was in a superficial femoral ar-
tery.22 Since then, several authors have studied balloon
angioplasty of superficial femoral arteries. Matsi et al23
obtained a 3-year secondary patency rate of 55% after
superficial femoral artery angioplasty in patients with leg
claudication. Alback et al24 noted a hemodynamic 2-year
patency rate of 55% after angioplasty, while Stanley et al 25
recorded a 2-year primary patency rate of 46% after angio-
plasty of superficial femoral and popliteal arteries. Stanley et
al25 did not recommend balloon angioplasty to treat clau-
dication because of the low patency rate.25 In comparison
to surgery, Shah et al26 noted 81% secondary patency at 5
years for above-the-knee vein grafts and Aune et al27
achieved a 55% primary and 71% secondary patency at 2
years with use of prosthetic grafts. In meta-analysis by
Pereira et al, the pooled primary graft patency was 57.4%
for above-knee polytetrafluoroethylene, 77.2% for above-
knee vein, and 64.8% for below-knee vein at 5 years; there
was a significant difference between above-knee grafts at 3,
4, and 5 years. The corresponding pooled secondary graft
patency was 73.2%, 80.1%, and 79.7%, respectively. 28 This
meta-analysis provided observational evidence on femoro-
popliteal bypass surgery for which the randomized evidence
is scarce. Above-knee vein and below-knee vein performed
better than above-knee popliteal and should be used when-
ever possible to reduce the gap between the best practice
and the true practice.
The results of our meta-analysis suggest that stent
placement in the femoropopliteal occlusive disease does not
increase the patency rate when compared with angioplasty
alone at 1 year. Eight studies were included in the final
analysis that gave a total of 1020 patients. The average
Jadad score was 2 showing the quality of studies included in
the meta-analysis.
Only two studies compared self-expandable stents with
balloon angioplasty with slightly better result toward the
stent group but not overall statistically significant results.
Heterogeneity was assessed between studies. Two variables
were used to assess heterogeneity in all those studies: 1-year
patency rate and postoperative ABI. Those variables were
not associated with a statistically significant regression pa-
rameter (P  .062 with an I-squared of 55.274 for the
primary patency at 1-year, P .519 with an I-squared of 0
for the postoperative ABI). We concluded that heteroge-
neity could not be explained, but the absence of others
significant data might have influenced it. The other issue in
the angioplasty group is that secondary patency, which was
achieved either by re-angioplasty to the lesion or implanta-
tion of a stent, was better than the primary patency.
Two meta-analyses have been published on femoro-
popliteal angioplasty and stenting up to date. The first by
Hunink et al estimate the patency results of percutaneous
transluminal angioplasty and bypass surgery in the treat-
ment of femoropopliteal arterial disease. But stenting re-
sults of the femoropopliteal segment were not included.5
The second meta-analysis by Muradin et al6 included 923
balloon angioplasty and 473 stent implantations. Com-bined 3-year patency rates after balloon dilation were 61%
(SE, 2.2%) for stenoses and claudication, 48% (SE, 3.3%)
for occlusions and claudication, 43% (SE, 4.1%) for steno-
ses and critical ischemia, and 30% (SE, 3.7%) for occlusions
and critical ischemia. The 3-year patency rates after stent
implantation were 63% to 66% (SE, 4.1%) and were inde-
pendent of clinical indication and lesion type. Publication
bias could not be ruled out. They concluded that balloon
dilation and stent implantation for claudication and steno-
sis had similar long-term patency rates. For more severe
femoropopliteal disease, the results of stent implantation
seem more favourable.
Most of the limitations in our meta-analysis were attrib-
utable to different factors. First, one of the studies is not yet
published, so all data is not available. The sensitivity analysis
done by removing this study did not impact on the patency
outcome at 1 year. There were few studies with missing
results, which we believe could have influenced the out-
come of endovascular therapy, mainly the influence of renal
failure patients, the usage of antiplatelet therapy, the anal-
ysis of data between diabetic and non-diabetic patient, and
the usage of cholesterol lowering therapy.
Second, all studies did not report the result according to
the standard of reporting of the Society of Vascular Surgery/
International Society of Cardiovascular Surgery.29
Third, not in any study were patients followed-up to 4
years, which we believe could have different results than
that which we have presented, and possibly show a better
outcome in the stenting group.
Fourth, the use of different types of stent technology
may impact on the outcome. All nitinol stents are not
equivalent. Some are very flexible (for example, IntraCoil,
Sinus Slex, Expander, and SMART Stent) and can be
implanted at locations where there is an angulation. Others,
such as the Symphony, are more rigid. Some may even
break when they are bent or placed in a flexion site (for
example, Sinustent and Memotherm).
The results of the SIROCCO II trial were not included
in this analysis because they compared the bared stent vs
sirolimus-eluting SMART stent. After 6 months, the
sirolimus-eluting SMART stent and the bare SMART
stent were highly effective in revascularization of the SFA
and in maintenance of its patency. These results confirm
findings from a similar study in 36 patients (SIROCCO I),
of whom 18 received the sirolimus-eluting stent and 18
received the bare metal stent.30 The cumulative in-stent
restenosis rates according to duplex ultrasound were 4.7%,
9.0%, 15.6%, and 21.9%, respectively, at 6, 9, 18, and 24
months; the rates did not differ significantly between the
treatment groups. At 24 months, the restenosis rate in the
sirolimus group was 22.9% vs 21.1% in the bare stent group
(P .05). Although there was a trend in the SIROCCO II
trial for greater efficacy in the sirolimus-eluting stent group,
there were no statistically significant differences in any of
the variables with lower fracture rate.31
Our conclusions should be viewed in the light of study-
design considerations and all limitations as stated above,
which may have an impact of the outcome of stenting and
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analysis of published articles on stent implantation and
balloon dilation for femoropopliteal arterial disease suggest
that stent implantation does not improve the patency but it
may be a useful adjunct to balloon dilation. Publication
bias, however, cannot be ruled out. A potential clinical
concern associated with placement of a femoropopliteal
stent is the occurrence of stent fractures in the long-term
and its impact on restenosis rate. Fracture rates were 19% for
Wallstents after a mean 43  24 months, 28% for SMART
stents after mean 32  16 months, and 2% for Dynalink/
Absolute stents after a mean 15  9 months. In-stent reste-
nosis rates at 1, 2, and 3 years were 46%, 66%, and 72% forwall
stents compared with 20%, 36%, and 53% for nitinol stents
(P  .001), respectively, without significant difference be-
tween the two nitinol stent groups (P .59).32
There is a considerable risk of stent fractures after long
segment femoral artery stenting, which is associated with a
higher in-stent restenosis and reocclusion rate.
According to Kaplan-Meier estimates, the primary pa-
tency rate at 12 months was significantly lower for patients
with stent fractures (41.1% vs 84.3%, P  .0001).33
In conclusion, stent placement still remains controver-
sial and it may be useful as a last resort procedure to save a
failed femoropopliteal balloon dilation procedure. Further
research addressing the insufficiency of the previous re-
search is required to identify suitable patients for primary
stenting and the impact of stent fracture and thrombosis on
long-term patency rate.
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